An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease by B.N. Lizama, H.A. North, K. Pandey, C. Williams, D. Duong, E. Cho, V. Di Caro, L. Ping, K. Blennow, H. Zetterberg, J. Lah, A.I. Levey, M. Grundman, A.O. Caggiano, N.T. Seyfried, M.E. Hamby

Get full text